SCHEMBL6703389

SCHEMBL6703389

CSc1ccc(NC(=O)c2ccc3ccn(CCOc4ccccc4)c(=O)c3c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 5/20 0.43
DGAT1 O75907 1/20 0.41
RAB9A P51151 4/20 0.40
NPC1 O15118 4/20 0.40
CHRNB2 P17787 2/20 0.40
CHRNB4 P30926 2/20 0.40
CHRNA3 P32297 2/20 0.40
CHRNA7 P36544 2/20 0.40
CHRNA4 P43681 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
F2 P00734 1/20 0.40
PLG P00747 1/20 0.40
PLAU P00749 1/20 0.40
PLAT P00750 1/20 0.40
KLKB1 P03952 1/20 0.40
KLK1 P06870 1/20 0.40
PRSS1 P07477 1/20 0.40
CHRNA10 Q9GZZ6 1/20 0.40
CHRNA9 Q9UGM1 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6697485 0.90 KCNA5 (0.48) MCHR1DGAT1RAB9ANPC1SMN1; SMN2
SCHEMBL6703386 0.84 PARP10 (0.43) SMN1; SMN2MEN1KMT2AGAAPOLB
SCHEMBL2118644 0.82 HDAC6 (0.46) SMN1; SMN2MEN1KMT2AGAAMAPK1
SCHEMBL6703820 0.80 MAPK1 (0.56) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL6702695 0.80 MEN1 (0.48) SMN1; SMN2MEN1KMT2AGAAPOLB
SCHEMBL2117041 0.77 HDAC6 (0.44)
SCHEMBL6700908 0.76 MMP13 (0.55) RAB9ANPC1SMN1; SMN2LMNAMEN1
SCHEMBL6699591 0.76 KDM4E (0.54) RAB9ANPC1SMN1; SMN2LMNAKDM4E
SCHEMBL2619344 0.76 SMPD1 (0.50) SMN1; SMN2MEN1KMT2AGAAMAPK1
SCHEMBL2116432 0.75 HDAC6 (0.56) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040044000-A1 Isoquinoline derivatives as matrix metalloproteinase inhibitors BUNKER AMY MAE (US) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044000-A1 Isoquinoline derivatives as matrix metalloproteinase inhibitors MMP1, MMP13, MMP9 MCHR1 4120/4885DGAT1 3456/4885RAB9A 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.